- Home
- LXEO vs CRDL Comparison
LXEO vs CRDL Comparison
Compare LXEO & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- CRDL
- Stock Information
- Founded
- LXEO 2017
- CRDL 2017
- Country
- LXEO United States
- CRDL Canada
- Employees
- LXEO N/A
- CRDL N/A
- Industry
- LXEO
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LXEO
- CRDL Health Care
- Exchange
- LXEO Nasdaq
- CRDL Nasdaq
- Market Cap
- LXEO 93.9M
- CRDL 80.1M
- IPO Year
- LXEO 2023
- CRDL N/A
- Fundamental
- Price
- LXEO $2.78
- CRDL $1.23
- Analyst Decision
- LXEO Strong Buy
- CRDL Strong Buy
- Analyst Count
- LXEO 6
- CRDL 3
- Target Price
- LXEO $18.50
- CRDL $9.00
- AVG Volume (30 Days)
- LXEO 984.8K
- CRDL 156.5K
- Earning Date
- LXEO 05-12-2025
- CRDL 05-14-2025
- Dividend Yield
- LXEO N/A
- CRDL N/A
- EPS Growth
- LXEO N/A
- CRDL N/A
- EPS
- LXEO N/A
- CRDL N/A
- Revenue
- LXEO N/A
- CRDL N/A
- Revenue This Year
- LXEO N/A
- CRDL N/A
- Revenue Next Year
- LXEO N/A
- CRDL N/A
- P/E Ratio
- LXEO N/A
- CRDL N/A
- Revenue Growth
- LXEO N/A
- CRDL N/A
- 52 Week Low
- LXEO $1.45
- CRDL $0.77
- 52 Week High
- LXEO $19.50
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- LXEO 45.92
- CRDL 59.43
- Support Level
- LXEO $2.51
- CRDL $1.19
- Resistance Level
- LXEO $2.91
- CRDL $1.31
- Average True Range (ATR)
- LXEO 0.38
- CRDL 0.07
- MACD
- LXEO -0.04
- CRDL 0.01
- Stochastic Oscillator
- LXEO 33.62
- CRDL 66.91
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.